SecBot SecBot
8-K ·Filed Nov 12, 2026

RLMD

RELMADA THERAPEUTICS, INC.
NEUTRAL
Impact 4/10
Horizonweeks Processed4d 10h ago SEC0001213900-26-118933
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

The key catalyst is the year-end 2026 IND submission for NDV-01; any delay or FDA feedback will drive the next significant move. The 18-month durability data is supportive but preliminary. Monitor the Q4 2026 update for IND status and SPECTRUM enrollment initiation.

DirectionNeutral
Confidencehigh
Horizonweeks

Drugs in focus

RLMD drug pipeline →

NDV-01

▲ Bullish Named in this 8-K
Impact
Phase
Phase 2 completed; preparing for Phase 3 (SPECTRUM program)
Time to market
If the IND is cleared by early 2027 and Phase 3 SPECTRUM program proceeds smoothly, potential FDA submission could be 2029-2030, assuming positive pivotal data. The drug is still pre-Phase 3.
Next catalyst
None dated

What to watchThe next catalyst is the NDV-01 IND submission, which Relmada expects by year-end 2026 (about 6 weeks away). A successful IND clearance would allow the Phase 3 SPECTRUM program to begin, while any delay or FDA clinical hold would be sharply negative. The Q4 2026 corporate update will likely confirm the submission status.

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1
Entry
$4.21
T+0 close · Nov 12, 2026 · via day close
Latest settled
−14.25%
T+1 · $3.61
Vs SPY
−12.34%
α at T+1
Next horizon
T+5
in 3d
  1. T+0 · Nov 13 $4.21entry
  2. T+1 · 20h ago −14.25%α −12.34% · $3.61
  3. T+5 · in 3d Pending
  4. T+20 · in 27d Pending
  5. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Relmada reported Q3 2026 net loss of $13.9M ($0.12/share), wider than the $10.1M loss in Q3 2025, driven by increased R&D spending on NDV-01 and sepranolone trial preparation. The company highlighted positive 18-month Phase 2 durability data for NDV-01 in NMIBC and confirmed it remains on track to submit the NDV-01 IND by year-end 2026. Cash of $202.1M is expected to fund operations through 2029.

Key Financial Metrics

EPS
−$0.12
Revenue
$0.00
est $0.00

Key Facts

  • Q3 2026 net loss of $13.9M ($0.12/share) vs $10.1M ($0.30/share) in Q3 2025
  • R&D expense increased to $9.2M from $4.0M year-over-year due to NDV-01 and sepranolone preparation costs
  • Cash, cash equivalents and short-term investments of $202.1M as of September 30, 2026
  • NDV-01 CMC program on track for IND submission by year-end 2026
  • 86% of evaluable 12-month complete responders remained in CR at 18 months in Phase 2 study
  • Phase 3 program renamed SPECTRUM with two independent registrational pathways unchanged
  • Sepranolone IND submission also on track for year-end 2026

Financial Impact

Net loss widened by $3.8M YoY; cash burn from operations was $12.6M in Q3 2026 vs $6.7M in Q3 2025

net lossR&D expensecash burn

Risk Factors

  • IND submission could be delayed beyond year-end 2026
  • Phase 3 SPECTRUM program may not replicate Phase 2 efficacy or safety results
  • Two BCG-naive patients progressed to muscle-invasive disease at Month 15, a potential safety signal
  • Cash burn is accelerating as R&D spending increases for Phase 3 readiness

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
90% bullish (10 analysts)

Investment Themes

Documents Analyzed

This report is based on 7 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001213900-26-118933
Document: ea031205701ex99-2.htm0001213900-26-118933
Document: ea0312057-8k_relmada.htm0001213900-26-118933
Document: 0001213900-26-118933-index-headers.html0001213900-26-118933
Document: 0001213900-26-118933-index.html0001213900-26-118933
Document: 0001213900-26-118933.txt0001213900-26-118933
8-K Data (Synthetic)0001213900-26-118933

Track record

11 reports on RLMD

Performance horizon

2 of 3 bullish or bearish reports moved the stock their way by T+20. Best: +38.81% at T+60 after the May 13, 2026 report. 2 of 3 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Bearish 5/10 Entry $3.54 Now $3.61 −1.98% settles Dec 15
  2. Nov 16, 2026today 8-K Neutral 3/10 Entry $4.16 Now $3.61 −13.23% settles Dec 15
  3. Nov 12, 20264d ago 8-K Neutral 4/10 Viewing Entry $4.21 Now $3.61 −14.25% settles Dec 14
  4. Sep 11, 20269w ago Insider Cluster Bullish 6/10 Entry $4.52 to $3.39 Now $3.61 −20.13% ▼ −25.00% −26.87% vs SPY
  5. May 13, 202626w ago S-3ASR Bearish 6/10 Entry $7.42 to $6.65 Now $3.61 +51.35% ▲ +10.38% +9.52% vs SPY
  6. May 12, 202626w ago 8-K Neutral 4/10 Entry $7.49 to $6.52 Now $3.61 −51.80% ▼ −12.95% −12.34% vs SPY
  7. Apr 17, 202630w ago DEFA14A Neutral 3/10 Entry $7.37 to $6.34 Now $3.61 −51.02% ▼ −13.98% −18.18% vs SPY
  8. Apr 3, 202632w ago S-3 Neutral 3/10 Entry $6.90 to $7.41 Now $3.61 −47.68% ▲ +7.39% −1.59% vs SPY
  9. Mar 19, 202634w ago Press Release Bullish 8/10 Entry $6.07 to $7.37 Now $3.61 −40.53% ▲ +21.42% +12.10% vs SPY
  10. Mar 12, 202635w ago Press Release Neutral 3/10 Entry $6.15 to $7.29 Now $3.61 −41.30% ▲ +18.54% +16.56% vs SPY
Showing 10 of 11

US Market Status

Market Closed · Opens in 6h 35m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 12, 2026